Cartesian Therapeutics (RNAC) Goodwill & Intangibles (2023 - 2026)

Cartesian Therapeutics (RNAC) has reported Goodwill & Intangibles for 4 consecutive years, with $142.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Goodwill & Intangibles fell 28.53% year-over-year to $142.1 million; the TTM figure through Mar 2026 stood at $142.1 million (down 28.53% YoY), while the FY2025 annual figure was $142.1 million, down 28.53% from the prior year.
• Goodwill & Intangibles held at $142.1 million in Q1 2026 per RNAC's latest filing, from $142.1 million in the prior quarter.
• Across five years, Goodwill & Intangibles topped out at $198.8 million in Q4 2023 and bottomed at $142.1 million in Q4 2025.
• Historically, Goodwill & Intangibles has averaged $187.4 million across 4 years, with a median of $198.8 million in 2023.
• Annual changes were most pronounced in 2024 — Goodwill & Intangibles changed 0.0% — and 2025, when it slipped 28.53%.
• Cartesian Therapeutics' Goodwill & Intangibles stood at $198.8 million in 2023, then changed by 0.0% to $198.8 million in 2024, then retreated by 28.53% to $142.1 million in 2025, then changed by 0.0% to $142.1 million in 2026.
• Business Quant data shows RNAC's Goodwill & Intangibles at $142.1 million in Q1 2026, $142.1 million in Q4 2025, and $198.8 million in Q3 2025.